Company overview. Sun Pharma Global FZE (often "Sun Pharma Global" or "SPG") is a free-zone limited liability establishment incorporated on November 25, 2008, and registered at Office 43, Block Y, SAIF Zone, Sharjah, United Arab Emirates. It is a wholly owned subsidiary of Sun Pharma Global Inc. (BVI), itself a wholly owned subsidiary of Sun Pharmaceutical Industries Ltd. (Sun Pharma), the Mumbai-based public company listed on Indian exchanges (NSE: SUNPHARMA). Sun Pharma reported roughly 43,000 employees and FY2025 revenue of about US$5.6–6.3 billion, with a market cap of roughly US$45 billion as of early 2026. A 2018 regulatory filing put SPG's standalone net assets at about US$1.96 billion (figures dated).
Products / services / operations. SPG is engaged in manufacturing, general trading, and exporting pharmaceutical formulations, plus investment and financing activities, according to Sun Pharma corporate filings. In U.S. regulatory practice, it is one of the Sun Pharma group entities that files Abbreviated New Drug Applications (ANDAs) with the FDA seeking approval to market generic versions of brand-name drugs, coordinating with parent Sun Pharmaceutical Industries Ltd. and U.S. subsidiary Sun Pharmaceutical Industries, Inc.
Patent-litigation posture. SPG is an operating company — a defendant, not a plaintiff, in the tracked docket. Its single tracked case is a Hatch-Waxman ANDA patent suit brought by an innovator (Novartis), a typical posture for generic-drug firms. The case sits in the District of Delaware, the standard venue for ANDA litigation, not a plaintiff-friendly outlier like the Eastern District of Texas.
Notable case. The tracked matter is Novartis Pharmaceuticals Corp. v. Sun Pharma Global FZE et al. (D. Del., filed November 23, 2021; terminated April 2023), which also named Sun Pharmaceutical Industries Ltd. and Sun Pharmaceutical Industries, Inc. as co-defendants. The suit concerned SPG's ANDA for a generic version of Novartis's Xiidra® (lifitegrast ophthalmic solution) and cited five Novartis formulation patents (e.g., U.S. Patent Nos. 11,058,677 and 9,353,088). Novartis alleged the Sun entities "acted collaboratively" in preparing and submitting the ANDA; SPG has historically denied being a proper party in such coordinated filings.